Sunitinib and Pterostilbene Combination Treatment Exerts Antitumor Effects in Gastric Cancer via Suppression of PDZD8.

Abstract

The use of molecular-targeted drugs in the treatment of gastric cancer is increasing. However, the variety of molecular-targeted drugs in gastric cancer is still limited, and the development of new molecular-targeted therapies is required. The effect of combining sunitinib (SUN) with pterostilbene (PTE) on the human gastric cancer cell lines TMK1 and MKN74 was examined in in vitro and in vivo. Compared with SUN or PTE treatment alone, cotreatment induced pronounced suppression of cell proliferation, with a marked increase in oxidative stress. SUN was associated with a significant retention of mitochondrial Fe2+. SUN-treated cells decreased expression of PDZ domain-containing protein 8 (PDZD8). Knockdown of PDZD8 in both cells induced Fe2+ retention, and siPDZD8+PTE markedly suppressed cell proliferation with suppressed oxidative phosphorylation, as did the combination of SUN+PTE. In a nude mouse tumor model, a pronounced antitumor effect was observed with SUN+PTE treatment compared to SUN alone. PDZD8 may be a newly discovered off-target for SUN, and that the combined use of PTE with SUN significantly promotes antitumor activity in gastric cancer cell lines. The combined use of SUN and PTE might be a new molecular-targeted therapy for gastric cancer.

• Authors: Yudai Hojo, Shingo Kishi, Shiori Mori, Rina Fujiwara-Tani, Takamitsu Sasaki, Kiyomu Fujii, Yukiko Nishiguchi, Chie Nakashima, Yi Luo, Hisashi Shinohara, Hiroki Kuniyasu
• Journal: International journal of molecular sciences (Int J Mol Sci) Vol. 23 Issue 7 (Apr 04 2022) ISSN: 1422-0067 [Electronic] Switzerland
• PMID: 35409367 (Publication Type: Journal Article)

Chemical References

• Stilbenes
• pterostilbene
• Sunitinib

Topics

• Animals
• Apoptosis
• Cell Line, Tumor
• Mice
• Mitochondria
• Stilbenes (pharmacology, therapeutic use)
• Stomach Neoplasms (drug therapy)
• Sunitinib (pharmacology, therapeutic use)